Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.81 USD | +2.78% | -1.03% | -58.99% |
30/05 | Evotec Partners With French Institutions, Company to Research Obesity | MT |
30/05 | Evotec Joins Collaboration to Identify New Therapies for Obesity, Metabolic Diseases | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 48% by 2026.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-58.99% | 166.41Cr | - | ||
+51.50% | 5.46TCr | B- | ||
-4.72% | 3.99TCr | B | ||
+37.77% | 3.88TCr | A | ||
+15.75% | 2.69TCr | B- | ||
-12.56% | 2.62TCr | C | ||
-21.63% | 1.88TCr | B | ||
+25.62% | 1.22TCr | B+ | ||
+1.86% | 1.22TCr | B+ | ||
+26.99% | 1.19TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- EVT Stock
- EVO Stock
- Ratings Evotec SE